After meniscectomy, many patients ask whether meniscus tissue can regenerate. Learn what stem cell research shows, who may be a candidate, and realistic expectations.
Meniscus tissue does not regrow on its own after a meniscectomy. The adult meniscus has very limited blood supply in most of its volume, which means its capacity for self-repair is poor. However, early-stage research into mesenchymal stem cell (MSC) therapy suggests it may support the biological environment in which some tissue repair is possible — not by regenerating a full new meniscus, but by modulating inflammation, slowing cartilage deterioration, and possibly stimulating localised cellular activity in the remaining meniscal tissue. This is a meaningful distinction. What research currently shows is not full regrowth. It is something more modest — and in clinical terms, often more useful — than that headline suggests.
If you've had a partial or total meniscectomy — whether months or years ago — you probably weren't told much about what happens next. Perhaps you were told the remaining cartilage would 'compensate'. Perhaps you've since developed medial or lateral knee pain, early osteoarthritis, or a grinding sensation that wasn't there before surgery. And perhaps you've searched, repeatedly, for something that might help.
The meniscus is a C-shaped wedge of fibrocartilage sitting between the femur and tibia. There are two in each knee — medial (inner) and lateral (outer). Their functions are several and significant: they absorb roughly 50–70% of compressive load during weight-bearing, distribute that load across a wider surface area, stabilise the joint against rotational forces, and — critically — protect the underlying articular cartilage from concentrated stress.
The meniscus has three vascular zones. The outer third — the 'red zone' — has reasonable blood supply and can sometimes heal after repair. The inner two-thirds — the 'white zone' — is avascular. No blood flow means no platelet delivery, no inflammatory cascade, no healing signal. Cells in the white zone simply cannot access the resources they'd need to repair damage. This is why meniscal tears in the inner zone rarely heal without intervention, and why once tissue is removed, it does not return through natural biology alone.
Mesenchymal stem cells — particularly those derived from umbilical cord tissue (Wharton's jelly) — are increasingly studied for their capacity to modulate inflammation and support tissue homeostasis. When delivered directly into the knee joint via intra-articular injection, MSCs do not typically engraft and become new meniscus tissue. That would require scaffolding, vascularisation, and a biological niche that the post-meniscectomy knee doesn't naturally provide.
The evidence base for MSC therapy in meniscal and knee cartilage conditions is still developing, but it is not empty. Several well-designed studies inform what we can say — and what we cannot.
Meniscus regrowth — in the sense of a full, functional, vascularised fibrocartilage structure replacing what was removed — has not been demonstrated in clinical trials in humans. Tissue engineering and scaffold-based approaches are being studied in research settings, some combining MSCs with biomaterial scaffolds implanted surgically. These are promising but remain experimental. No such approach has achieved regulatory approval as a standard clinical treatment.
Not every patient who has had a meniscectomy is a suitable candidate for MSC therapy. Eligibility is determined through individual clinical assessment, not a general checklist. But there are patterns that guide the evaluation.
MSC therapy is best understood as a complement to — not a replacement for — physiotherapy and conventional management. In our clinic, we do not recommend stem cell treatment as a standalone approach. It is part of a broader care plan that includes rehabilitation, load management, and regular follow-up.
For international patients considering MSC therapy for post-meniscectomy knee conditions, our process begins before you arrive. Here is what to expect.
The MSCs used at our clinic are derived from ethically donated umbilical cord tissue (Wharton's jelly). This is an allogeneic source — meaning the cells come from screened, consenting donors, not from the patient themselves. Umbilical cord MSCs are chosen because they are harvested without invasive procedures, are consistently high-potency, and are well-characterised in the research literature.
Patients sometimes arrive hoping MSC therapy will regenerate a full, functional meniscus. It won't — and any provider suggesting otherwise is overstating the evidence. What many post-meniscectomy patients do report, based on published data and clinical observation, is a different kind of meaningful change.
Intra-articular MSC injection has a generally favourable safety profile in the published literature. The most commonly reported adverse events are transient: post-injection swelling, mild warmth at the injection site, and temporary increase in joint discomfort lasting 24–72 hours. These are typical inflammatory responses to any intra-articular injection and usually resolve without intervention.
This is one of the most common questions international patients ask — and it deserves a direct, honest answer.
Stem cell therapy is not an emergency treatment. If you have acute joint infection, unexplained severe pain, fever with joint swelling, or sudden significant deterioration in knee function — see your orthopaedic surgeon first. These may indicate septic arthritis, acute ligament injury, or other structural problems that require urgent conventional assessment, not regenerative medicine.
In a strict anatomical sense, no — full meniscus regrowth has not been demonstrated in human clinical trials. What some studies have shown is partial volume changes in residual meniscal tissue and cartilage preservation at 12-month MRI follow-up in patients receiving intra-articular MSC injections. These are meaningful biological signals, but they do not equate to full structural regeneration of the native meniscus.
PRP (Platelet-Rich Plasma) concentrates growth factors from the patient's own blood and delivers them to the joint to stimulate local healing responses. MSC therapy introduces live mesenchymal stem cells with broader immunomodulatory and paracrine signalling capabilities. MSCs actively communicate with surrounding cells, modulate inflammatory pathways via cytokines, and release exosomes carrying genetic signals. PRP is autologous and simpler to prepare; MSC therapy is more complex, requires GMP processing and donor screening, and — based on current evidence — offers a broader range of biological effects.
Most protocols studied in clinical trials involve a single intra-articular injection, followed by clinical and imaging review at 6 months to assess response. In some cases, a second injection is considered at 6–12 months if partial response is observed and the patient remains a suitable candidate. The decision is always made on an individual basis, not on a fixed commercial schedule. No responsible clinic should pre-commit a patient to multiple sessions without assessing initial response.
For patients with early- to moderate-stage post-meniscectomy osteoarthritis, MSC therapy may contribute to slowing cartilage deterioration and improving symptom burden — which could, in some patients, delay the progression to the point where knee replacement becomes necessary. This is not a guarantee, and it depends heavily on individual disease stage, activity level, and rehabilitation compliance. For patients already at advanced-stage disease, the calculus changes — and our medical team will advise honestly on whether MSC therapy is likely to be meaningful for a particular patient.
Ask about cell source and whether it is allogeneic or autologous. Ask what donor screening tests are performed and whether GMP-compliant processing is used. Ask how cell identity is verified — CD markers, viability testing. Ask about their adverse event monitoring and follow-up protocol. Ask what imaging is used to assess pre- and post-treatment response. Ask about the specific evidence they base their protocol on — not just that stem cells 'work', but which studies, which populations, which outcomes. A clinic that answers these questions clearly and without deflection is a clinic worth considering.
Safety depends on what cells are used, how they are prepared, how the injection is administered, and whether the patient is a suitable candidate. In the published literature, intra-articular MSC injection with properly screened and characterised cells has demonstrated a favourable short-term safety profile, with adverse events typically limited to transient injection-site reactions. MSC research overall has a clinical investigation history exceeding 15 years across multiple conditions — which informs the safety understanding. The intra-articular application specifically has a shorter dedicated evidence trail, and longer-term data beyond 2 years in this specific application is still accumulating. The honest answer is: it appears safe in well-conducted settings, and we have not seen it approved as standard care anywhere — which reflects where the evidence currently sits, not a red flag about the treatment itself.
If you have had a meniscectomy and are living with chronic knee pain, early osteoarthritis, or progressive joint deterioration, stem cell therapy may be worth a careful, medically supervised evaluation. Not as a guarantee. Not as a cure. But as a biologically rational, clinically supervised option with a growing evidence base and a meaningful safety record.
Meniscus Regrowth After Meniscectomy: Can Stem Cell Therapy Help?